A regulatory protocol for pharmacogenomics services

被引:6
作者
Bristol L.A. [1 ]
机构
[1] Arent Fox Kintner Plotkin/Kahn, PLLC, Washington, DC 20036-5339
关键词
D O I
10.1038/sj.tpj.6500079
中图分类号
学科分类号
摘要
[No abstract available]
引用
收藏
页码:83 / 86
页数:3
相关论文
共 13 条
[1]  
Medical devices, classification/reclassification
[2]  
restricted devices
[3]  
analyte specific reagents, 61 Fed. Reg. 10, 484 (1996) (21 C.F.R. Parts 809 & 864)
[4]  
FDA needs to regulate 'home brews, Nature Biotechnology, 14, (1996)
[5]  
Malinowski M.J., Blatt R.J.R., Tulane Law Review, 71, (1997)
[6]  
(1992)
[7]  
Emerging technologies. Are diagnostics not ready for the genetic revolution?, Genesis Report, 6, 4
[8]  
Genetic factors in drug therapy: Clinical and molecular pharmacogenetics, pp. 607-669, (1993)
[9]  
Scarlett T., The relationship among adverse reaction reporting, drug labeling, product liability and federal preemption, Food Drug Cosm. L.J, 46, (1991)
[10]  
Saltus R., Survey of labs new tests concerns genetics specialists, (1995)